Biotech RadarJobs updated

COMPANY

ImmunityBio

HQ: San Diego, CA source · immunitybio.com ↗ · West Coast

Clinical Phase 3

48 open jobs · last seen Oct 23, 2026 · 51 sources

Keywords: oncology infectious disease cancer infectious diseases Sepsis Non Small Cell Lung Cancer NMIBC Lymphopenia Urothelial Carcinoma Bladder Cancer Long COVID Pancreatic Cancer High-risk Prostate Cancer Relapsed B-Cell Non Hodgkin Lymphoma Non Muscle Invasive Bladder Cancer Head and Neck Squamous Cell Carcinoma Merkel Cell Carcinoma Melanoma Covid19 Metastatic Urothelial Carcinoma Locally Advanced Urothelial Carcinoma Urothelial Cancer Long COVID Syndrome Long Covid 19 HPV-Related Carcinoma Pancreatic Cancer Resectable B-ALL Leukemia NSCLC Stage IV Non-Hodgkin Lymphoma Refractory/ Relapsed Platinum-resistant Ovarian Cancer Glioblastoma NSCLC (Advanced Non-small Cell Lung Cancer) Metastatic NSCLC HPV-Positive Oropharyngeal Squamous Cell Carcinoma Oropharyngeal Squamous Cell Carcinoma Head and Neck Cancer Septic Shock Immunosuppression Critical Illness Acute Respiratory Distress Syndrome Severe Community-Acquired Pneum Community-Acquired Pneumonia

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

48Open jobs$255.0MRaised (2 yrs)83Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Specialist, Regulatory Pharmacologist-PromotionsSummit, NJOct 21, 2026Oct 14, 2026
Specialist III, BiometricsSummit, NJOct 21, 2026Oct 14, 2026
Principal Scientist, Regulatory CMCSummit, NJOct 21, 2026Oct 14, 2026
Senior Scientist, Regulatory CMCSummit, NJOct 21, 2026Oct 14, 2026
Senior Specialist, Regulatory AffairsSummit, NJOct 21, 2026Oct 14, 2026

See all 48 jobs

Timeline

  1. Trial start Phase 1: N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer source ↗
  2. Trial start Phase 2: NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis source ↗
  3. Trial start 1: Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Rese source ↗
  4. Trial start 2: Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation source ↗
  5. Trial start Phase 2: NAI for Sepsis With Persistent Lymphopenia source ↗
  6. Trial start 3: Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC source ↗
  7. Trial start Phase 3: ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer source ↗
  8. Trial start Phase 2: Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) source ↗
  9. Trial start Phase 3: Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia source ↗
  10. Trial start Phase 2: Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma source ↗
  11. Trial start Phase 2: Immunotherapy Before and After Surgery source ↗
  12. Trial start Phase 2: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. source ↗
  13. Trial start Phase 2: A Study to Assess Anktiva in Patients With Long Covid-19. source ↗
  14. Trial start Phase 2: Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma source ↗
  15. Trial start Phase 2: Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer source ↗
  16. Trial start Phase 1/Phase 2: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG source ↗
  17. Trial start Phase 3: Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lun source ↗
  18. Trial start Phase 2: A Study to Examine Anktiva for the Treatment of COVID-19. source ↗
  19. Trial start Phase 1: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma source ↗
  20. Raise Private placement: $80M (total, as published), announced Jul 25, 2025. Source: SEC filing. source ↗
  21. Trial start Phase 1: A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia source ↗
  22. Raise Private placement: $75M (total, as published), announced Apr 8, 2025. Source: SEC filing. source ↗
  23. Raise Follow-on offering: $100M (total, as published), announced Dec 11, 2024. Source: SEC filing. source ↗
  24. Trial start 2: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant H source ↗
  25. Trial start Phase 1: Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma source ↗

Showing 25 of 51 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $255.0M. Last 2 years.

Clinical trials (lead sponsor) Showing 50 of 83

RecordTitlePhaseStatusStartPrimary completion
NCT07783789NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With SepsisPhase 2Not yet recruitingOct 15, 2026May 12, 2028 (estimated)
NCT07217496N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerPhase 1Not yet recruiting2026-122028-01 (estimated)
NCT07123727A Study to Examine Anktiva for the Treatment of COVID-19.Phase 2RecruitingSep 4, 20252027-03 (estimated)
NCT05976828IBRX-042 In Participants With HPV-Associated TumorsPhase 1Active, not recruitingJun 14, 2024Sep 2, 2027 (estimated)
NCT07488884Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer1WithdrawnSep 1, 2026Jun 1, 2027 (estimated)
NCT07556757A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic LeukemiaPhase 1TerminatedApr 11, 2025Jul 1, 2026 (actual)
NCT06745908Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InPhase 3RecruitingOct 1, 20252028-09 (estimated)
NCT06334991Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaPhase 1Active, not recruitingAug 23, 20242027-10 (estimated)
NCT06710288A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer2RecruitingNov 6, 20242027-05 (estimated)
NCT06061809N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaPhase 2Active, not recruitingAug 7, 2024Dec 31, 2029 (estimated)
NCT07524257Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC3WithdrawnMay 29, 2026May 15, 2029 (estimated)
NCT07628062Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation2Not yet recruitingJul 22, 2026Dec 31, 2030 (estimated)
NCT03520686Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerPhase 3TerminatedMay 18, 2018Oct 13, 2025 (actual)
NCT07551544ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerPhase 3WithdrawnMay 15, 20262032-05 (estimated)
NCT06810141ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerNot listedAvailableNot listedNot listed
NCT07578558NAI for Sepsis With Persistent LymphopeniaPhase 2Not yet recruitingJul 6, 2026Aug 3, 2027 (estimated)
NCT07108036A Study to Assess Anktiva in Patients With Long Covid-19.Phase 2RecruitingNov 14, 20252026-10 (estimated)
NCT07492888Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)Phase 2WithdrawnApr 15, 2026Nov 15, 2026 (estimated)
NCT07492875Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaPhase 3WithdrawnApr 15, 2026Apr 15, 2029 (estimated)
NCT06765954Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.Phase 2WithdrawnDec 1, 2025Jan 31, 2031 (estimated)
NCT06765902Immunotherapy Before and After SurgeryPhase 2WithdrawnDec 15, 2025Jan 31, 2031 (estimated)
NCT07125872Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaPhase 2RecruitingNov 11, 2025May 25, 2027 (estimated)
NCT05981131Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)Not listedActive, not recruitingAug 17, 2023Aug 30, 2033 (estimated)
NCT05304936HCW9218 for Advanced Pancreatic CancerPhase 1/Phase 2CompletedOct 17, 2022Feb 15, 2025 (actual)
NCT05618925Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaPhase 1RecruitingAug 22, 2025May 15, 2026 (estimated)
NCT04050709QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersPhase 1CompletedJul 18, 2019Mar 30, 2021 (actual)
NCT02138734A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerPhase 1/Phase 2Active, not recruitingJul 21, 2014Sep 30, 2026 (estimated)
NCT06800963ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGPhase 1/Phase 2RecruitingOct 15, 20252028-02 (estimated)
NCT07477366Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaPhase 2Not yet recruiting2026-042027-12 (estimated)
NCT03228667QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsPhase 2Active, not recruitingDec 11, 2018Aug 31, 2029 (estimated)
NCT04390399Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerPhase 2Active, not recruitingJul 21, 2020Oct 13, 2025 (actual)
NCT04898543QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 1Active, not recruitingJun 21, 2021May 31, 2026 (estimated)
NCT06829823Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerPhase 2Not yet recruiting2025-112026-11 (estimated)
NCT03022825QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerPhase 2/Phase 3Active, not recruitingJun 2, 2017Oct 1, 2024 (actual)
NCT06956547Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation TherapyNot listedAvailableNot listedNot listed
NCT06040918Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By ApheresisPhase 1CompletedOct 4, 2023Sep 3, 2024 (actual)
NCT05370040THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 VaccinesPhase 1/Phase 2TerminatedMay 5, 2022Mar 11, 2024 (actual)
NCT03169764QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyPhase 1/Phase 2Withdrawn2017-122019-01 (estimated)
NCT03169790QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLPhase 1/Phase 2Withdrawn2017-122019-01 (estimated)
NCT03169738QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsPhase 1/Phase 2Withdrawn2018-022019-01 (estimated)
NCT03167164QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyPhase 1/Phase 2Withdrawn2017-122019-01 (estimated)
NCT03647423QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.Phase 1/Phase 2WithdrawnAug 31, 2018Aug 31, 2020 (estimated)
NCT03554109QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccinePhase 2Withdrawn2018-092020-06 (estimated)
NCT03175666QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyPhase 1/Phase 2Withdrawn2017-122019-01 (estimated)
NCT04845191COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesPhase 1/Phase 2Withdrawn2021-122021-12 (estimated)
NCT03167177QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyPhase 1/Phase 2Withdrawn2017-122019-01 (estimated)
NCT03197584QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyPhase 1/Phase 2Withdrawn2017-122019-02 (estimated)
NCT04843722COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesPhase 1/Phase 2Withdrawn2021-122021-12 (estimated)
NCT03574649QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer2Withdrawn2018-062018-08 (estimated)
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccinePhase 2Withdrawn2018-08Dec 30, 2019 (estimated)

Open jobs 48

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Specialist, Regulatory Pharmacologist-PromotionsSummit, NJOct 21, 2026Oct 14, 2026Senior
Specialist III, BiometricsSummit, NJOct 21, 2026Oct 14, 2026Mid
Principal Scientist, Regulatory CMCSummit, NJOct 21, 2026Oct 14, 2026Senior
Senior Scientist, Regulatory CMCSummit, NJOct 21, 2026Oct 14, 2026Senior
Senior Specialist, Regulatory AffairsSummit, NJOct 21, 2026Oct 14, 2026Senior
Senior Analyst, ERP SystemsEl Segundo CA MariposaOct 20, 2026Oct 21, 2026Not stated
Principal Specialist, Health AuthoritiesSummit, NJOct 19, 2026Oct 20, 2026Not stated
Senior Specialist, Health AuthoritiesSummit, NJOct 19, 2026Oct 20, 2026Not stated
Uro Oncology Business Manager – Indianapolis, INRemoteOct 15, 2026Oct 14, 2026Mid
Clinical Trials ManagerDunkirk NYOct 15, 2026Oct 14, 2026Mid
Clinical Research Associate, In-HouseDunkirk NYOct 15, 2026Oct 14, 2026Senior
Veeva Clinical AnalystDunkirk NYOct 15, 2026Oct 14, 2026Entry
Field Reimbursement Manager – North CentralRemoteOct 15, 2026Oct 14, 2026Senior
Corporate Account DirectorRemoteOct 15, 2026Oct 14, 2026Senior
Associate Director, Global Outsourcing & Budget ManagementRemoteOct 15, 2026Oct 14, 2026Senior
Research Associate I, Analytical DevelopmentTorrey Pines, CAOct 15, 2026Oct 14, 2026Entry
Senior Clinical Data ManagerDunkirk NYOct 9, 2026Oct 14, 2026Senior
Senior Contracts AdministratorDunkirk NYOct 9, 2026Oct 14, 2026Senior
Workday AnalystRemoteOct 9, 2026Oct 14, 2026Mid
Paralegal, Corporate ContractsDunkirk NYOct 9, 2026Oct 14, 2026Mid
Senior Accountant, General LedgerEl Segundo CA MariposaOct 9, 2026Oct 14, 2026Senior
Senior Research Associate, ImmunologyLouisville, COOct 9, 2026Oct 14, 2026Senior
Research Associate II, Analytical DevelopmentTorrey Pines, CAOct 9, 2026Oct 14, 2026Mid
IB Temporary - Medical Information SpecialistRemoteOct 8, 2026Oct 14, 2026Entry
BioProcess Engineer II, UpstreamLouisville, COOct 7, 2026Oct 14, 2026Mid
BioProcess Engineer II, DownstreamLouisville, COOct 7, 2026Oct 14, 2026Mid
Senior Specialist, Quality Control AnalyticalEl Segundo CA MariposaOct 7, 2026Oct 14, 2026Senior
Accounting ManagerEl Segundo CA MariposaOct 6, 2026Oct 14, 2026Mid
Senior Paralegal, Intellectual PropertyTorrey Pines CASep 23, 2026Oct 14, 2026Senior
Senior Clinical Trials ManagerRemoteSep 23, 2026Oct 14, 2026Senior
Clinical Implementation DirectorRemoteSep 23, 2026Oct 14, 2026Senior
DevOps Engineer2 locations (listed on the posting)Sep 23, 2026Oct 14, 2026Mid
Event ManagerRemoteSep 23, 2026Oct 14, 2026Senior
Specialist, Quality Control AnalyticalEl Segundo CA MariposaSep 23, 2026Oct 14, 2026Mid
Senior, IT GXP Systems SpecialistEl Segundo CA MariposaSep 23, 2026Oct 14, 2026Senior
Field Medical Director, South CentralRemoteSep 23, 2026Oct 14, 2026Senior
Field Medical Director - NortheastRemoteSep 23, 2026Oct 14, 2026Senior
Senior Scientist, Quality Control AnalyticalDunkirk NYSep 23, 2026Oct 14, 2026Senior
Specialist, Quality Control AnalyticalDunkirk NYSep 23, 2026Oct 14, 2026Mid
Senior Clinical Research Associate, Field MonitorRemoteSep 23, 2026Oct 14, 2026Senior
Medical Call Center RepresentativeEl Segundo CA MariposaSep 23, 2026Oct 14, 2026Entry
Principal Scientist, Upstream Process ScienceLouisville, COSep 23, 2026Oct 14, 2026Senior
Regulatory Documentation Specialist IIISummit, NJSep 23, 2026Oct 14, 2026Mid
Manager, Corporate Print Shop ServicesEl Segundo CA MariposaSep 23, 2026Oct 14, 2026Senior
Senior Human Resources Business PartnerEl Segundo CA MariposaSep 23, 2026Oct 14, 2026Senior
Senior AI Cyber Security EngineerDunkirk NYSep 23, 2026Oct 14, 2026Senior
Senior Security Engineer, AI Model and ApplicationDunkirk NYSep 23, 2026Oct 14, 2026Senior
Senior Metrology TechnicianDunkirk NYSep 23, 2026Oct 14, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at ImmunityBio on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback